
Opinion|Videos|January 29, 2025
Patient Experiences, Key Clinical Trial Outcomes of the Port Delivery System
Panelists discuss how the Port Delivery System (PDS) presents important considerations around adverse effects, patient selection criteria, and adoption challenges including surgical requirements and cost-benefit analyses that must be carefully weighed when integrating this technology into retinal practice.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Could you discuss the key outcomes from the ARCHWAY trial for PDS?
- The PDS Q24W was noninferior to monthly ranibizumab in terms of BCVA change from baseline
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Retina World Congress 2026: Uveitis risk rises as immune checkpoint inhibitor use expands
2
Laru-zova sustains visual function improvements at 12 months in XLRP gene therapy trial
3
The Retina TL;DR with Dr. Weng: Navigating the ocular risks of facial fillers with Jennifer Murdock, MD
4























